静脉甲泼尼龙冲击治疗与急性COVID-19患者院内死亡风险:全国临床队列研究
该研究为日本2020—2021年438家医院67,348例住院急性COVID-19患者的前瞻性队列,采用边际结构模型控制时间依赖偏倚,按有创机械通气(iMV)状态分层,比较静脉甲泼尼龙冲击治疗(每日500 mg或以上)与未用甲泼尼龙者院内死亡风险。结果显示,iMV患者接受冲击治疗与院内死亡风险降低相关(HR 0.59;95%CI 0.52-0.68),无需iMV者冲击治疗与死亡风险升高相关(HR 3.38;95%CI 3.02-3.79);iMV患者中冲击治疗获益大于中/高剂量甲泼尼龙(40-250 mg静脉)者(HR 0.80;95%CI 0.71-0.89)。作者认为冲击治疗可能使需iMV的危重患者获益。
要点
- 需有创机械通气的急性COVID-19患者,静脉甲泼尼龙冲击治疗(每日500 mg或以上)与院内死亡风险降低相关(HR 0.59;95%CI 0.52-0.68)。
- 无需有创机械通气的急性COVID-19患者,静脉甲泼尼龙冲击治疗与院内死亡风险升高相关(HR 3.38;95%CI 3.02-3.79)。
- iMV患者中,冲击治疗的获益大于中/高剂量甲泼尼龙(40-250 mg静脉)治疗(HR 0.80;95%CI 0.71-0.89)。
- 院内死亡率:无iMV者未用与用冲击治疗分别为2.3%与19.5%;iMV者分别为24.7%与28.6%。
- 研究采用边际结构模型控制时间依赖偏倚,以未用甲泼尼龙者为参照。
适用人群与场景
- 2020—2021年日本438家医院住院的急性COVID-19患者,共67,348例,按有创机械通气(iMV)状态分层。
处置流程与药物剂量
- 静脉甲泼尼龙冲击治疗定义为每日500 mg或以上;对照为未用甲泼尼龙及中/高剂量甲泼尼龙(40-250 mg静脉)。
研究设计与关键结果
- 研究类型:前瞻性队列研究,67,348例住院急性COVID-19患者,438家医院,2020—2021年日本;采用边际结构模型控制时间依赖偏倚,以未用甲泼尼龙者为参照。
- 研究期间共2400例死亡;无iMV患者未用与用甲泼尼龙冲击治疗的院内死亡率分别为2.3%与19.5%,iMV患者分别为24.7%与28.6%。
- 边际结构模型分析:iMV患者接受静脉甲泼尼龙冲击治疗与院内死亡风险降低相关(HR 0.59;95%CI 0.52-0.68)。
- 无iMV患者接受静脉甲泼尼龙冲击治疗与院内死亡风险升高相关(HR 3.38;95%CI 3.02-3.79)。
- iMV患者中,冲击治疗获益大于中/高剂量甲泼尼龙(40-250 mg静脉)治疗(HR 0.80;95%CI 0.71-0.89)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究;原文未报告证据等级或推荐强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,静脉甲泼尼龙呈剂量-反应效应,冲击治疗可能使需有创机械通气的急性COVID-19危重患者获益。
- 无需有创机械通气的急性COVID-19患者接受静脉甲泼尼龙冲击治疗与院内死亡风险升高相关(HR 3.38;95%CI 3.02-3.79)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Steroids are widely used to modulate the inflammatory reactions associated with coronavirus disease 2019 (COVID-19); however, the optimal upper limit dose of steroid use for acute COVID-19 care remains unclear and currently available data may suffer from a time-dependent bias of no effectiveness or reversed causation given the desperate situation of treatment during this pandemic. Accordingly, the aim of this study was to elucidate the impact of intravenous pulse therapy with methylprednisolone (500 mg or greater per day) on the risk of in-hospital mortality among patients with COVID-19 by controlling for time-dependent bias.
METHODS: We performed a prospective cohort study with 67,348 hospitalised acute COVID-19 patients at 438 hospitals during 2020-2021 in Japan. The impact of intravenous methylprednisolone pulse therapy on the risk of in-hospital mortality was examined based on hazard ratios (HRs) and 95% confidence intervals (95% CIs), with stratification according to the status of invasive mechanical ventilation (iMV). Time-dependent bias was controlled for in a marginal structural model analysis, with reference to patients without methylprednisolone therapy.
RESULTS: During the study period, 2400 patients died. In-hospital mortality rates of iMV-free patients without or with methylprednisolone pulse therapy were 2.3% and 19.5%, and the corresponding values for iMV-receiving patients were 24.7% and 28.6%, respectively. The marginal structural model analysis showed that intravenous pulse therapy with methylprednisolone was associated with a lower risk of in-hospital mortality among patients receiving-iMV (HR 0.59; 95% CI 0.52-0.68). In contrast, pulse therapy with methylprednisolone increased the risk of in-hospital mortality among iMV-free patients (HR 3.38; 95% CI 3.02-3.79). The benefits of pulse therapy for iMV-receiving patients were greater than in those treated with intermediate/higher doses (40-250 mg intravenously) of methylprednisolone (HR 0.80; 95% CI 0.71-0.89).
CONCLUSION: The results of our study suggest that intravenous methylprednisolone showed dose-response efficiencies, and pulse therapy may benefit critically ill patients with acute COVID-19, such as those requiring iMV.
参考来源
- Moromizato T, Sakaniwa R, Tokuda Y, et al. Intravenous methylprednisolone pulse therapy and the risk of in-hospital mortality among acute COVID-19 patients: Nationwide clinical cohort study. Crit Care. 2023. PMID: 36755340. doi:10.1186/s13054-023-04337-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。